BHCM
APGE icon

Brevan Howard Capital Management’s Apogee Therapeutics APGE Stock Holding History

Brevan Howard Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,085
Closed -$1.44M – 1926
2025
Q2 		$1.44M Buy
+33,085
New +$1.26M 0.01% 889

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Brevan Howard Capital Management's APGE Position: Q3 2025 in Review

Brevan Howard Capital Management sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 33,085 shares — an estimated $1.44M sold.

Brevan Howard Capital Management first reported a position in APGE in Q2 2025 and held it in 1 quarter. The position peaked at $1.44M in Q2 2025. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Brevan Howard Capital Management reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 33,085 Apogee Therapeutics shares in Q3 2025, an estimated $1.44M.
  • Brevan Howard Capital Management first reported a position in Apogee Therapeutics in Q2 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Apogee Therapeutics position peaked at $1.44M in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Brevan Howard Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.